-+ 0.00%
-+ 0.00%
-+ 0.00%

AIM IMMUNOTECH - PHASE 2 DURIPANC TOPLINE RESULTS EXPECTED IN Q1 2027; ADDITIONAL ANALYSES IN Q3 2027 - SEC FILING

Reuters·11/05/2026 14:17:46

Please log in to view news